Prenatal Cannabis Exposure Linked to Placental Changes and Schizophrenia Risk

New Research Adds Weight to Prenatal Cannabis Concerns

As cannabis legalization expands and social stigma fades, a growing body of research is raising important questions about one population that remains particularly vulnerable: developing fetuses. A recent study has found that cannabis use during pregnancy may leave molecular "fingerprints" in the placenta — genetic markers that overlap with signatures previously linked to schizophrenia and other mental health conditions in offspring.

The findings don't prove that cannabis directly causes schizophrenia. But they add to a mounting evidence base that suggests prenatal cannabis exposure carries meaningful risks that prospective parents should understand before making decisions about use during pregnancy.

What the Study Found

Researchers examined placentas from pregnancies where the mother had used THC-containing cannabis products. When compared to placentas from non-exposed pregnancies, the THC-exposed samples showed increased expression of several genes that match human placental markers previously associated with schizophrenia risk.

The mechanism appears to involve the endocannabinoid system, which plays a critical role in fetal brain development. THC — the primary psychoactive compound in cannabis — crosses the placental barrier and interacts with CB1 receptors in the developing fetal brain. These receptors are involved in neural circuit formation, neurotransmitter release, and synaptic pruning — processes that, when disrupted, have been implicated in the development of psychotic disorders.

The placental gene expression changes observed in the study suggest that THC exposure may alter the molecular environment in which the fetus develops, potentially setting the stage for psychiatric vulnerability that manifests years or decades later.

Building on a Broader Evidence Base

This research doesn't exist in isolation. Over 70 cannabis-related studies have been published in 2026 alone, and several have focused specifically on prenatal exposure risks.

A comprehensive systematic review from Oregon Health & Science University, published in 2025, found that consuming cannabis while pregnant appears to increase the odds of preterm birth, low birth weight, and infant death. The review incorporated eight new studies since its previous update, raising the certainty of evidence from "very-low-to-low" to "moderate" for increased odds of low birth weight, preterm birth, and babies being small for their gestational age.

Earlier research has documented associations between prenatal cannabis exposure and behavioral outcomes in children, including increased impulsivity, attention difficulties, and — in some longitudinal studies — small but measurable increases in psychosis-related traits during adolescence.

A separate study from Johns Hopkins University, published in 2025, found that cannabis use disorder in teenagers was associated with a 52% higher risk of developing schizophrenia. While that study focused on adolescent rather than prenatal exposure, it reinforces the broader concern about THC's effects on developing brains at critical periods.

The Prevalence Problem

These findings arrive against a backdrop of increasing cannabis use during pregnancy. National survey data indicates that cannabis use among pregnant women has been rising steadily, driven in part by perceptions that cannabis is "natural" and therefore safe, and by the use of cannabis products for pregnancy-related nausea.

Some dispensaries and online forums actively recommend cannabis for morning sickness — a practice that concerns public health researchers. While THC can indeed reduce nausea, the downstream effects on fetal development may outweigh the short-term symptom relief.

Interestingly, a study published in JAMA Network Open found that mandatory warning sign policies at dispensaries — signs informing customers about risks of cannabis use during pregnancy — are not associated with reduced cannabis use during pregnancy. The finding suggests that education alone may be insufficient and that healthcare providers need to play a more active role in counseling patients about prenatal cannabis risks.

What Experts Say

Researchers stress the importance of nuance. The placental fingerprint study does not prove that prenatal cannabis exposure definitively causes schizophrenia. Schizophrenia is a complex condition influenced by genetics, environmental factors, and neurodevelopmental processes that unfold over years. THC exposure during pregnancy appears to be one risk factor among many — not a singular cause.

However, the precautionary principle suggests that pregnant individuals should avoid THC-containing products when possible. CBD — the non-psychoactive cannabinoid — has not been associated with the same placental or neurodevelopmental changes, but research on prenatal CBD exposure is still limited, and most experts recommend caution with all cannabis products during pregnancy.

The American College of Obstetricians and Gynecologists (ACOG) has consistently recommended against cannabis use during pregnancy and breastfeeding. The American Academy of Pediatrics has issued similar guidance.

The Knowledge Gap

Despite the growing body of research, significant gaps remain. Most studies on prenatal cannabis exposure are observational — meaning they can identify associations but can't establish causation with certainty. Conducting randomized controlled trials on cannabis use during pregnancy is ethically impossible, which means researchers must rely on natural variation in use patterns and control for confounding variables like socioeconomic status, co-substance use, and pre-existing mental health conditions.

The potency question adds another layer of complexity. Today's cannabis products are significantly more potent than those available even a decade ago, with THC concentrations in flower averaging above 20% and concentrates exceeding 80%. Most historical research on prenatal exposure was conducted when THC concentrations were far lower, meaning current products may carry proportionally greater risk.

Practical Takeaways

For pregnant individuals or those planning to become pregnant, the current evidence supports several practical recommendations.

First, THC-containing products should be avoided during pregnancy. While the absolute risk of any single adverse outcome remains statistically small, the cumulative evidence of associations with preterm birth, low birth weight, and neurodevelopmental changes is now at a moderate certainty level — strong enough to warrant precaution.

Second, patients experiencing pregnancy-related nausea should discuss alternatives with their healthcare provider. Evidence-based treatments for morning sickness include ginger supplements, vitamin B6, doxylamine, and prescription medications like ondansetron — options that have been studied more extensively in pregnant populations.

Third, the postpartum period also warrants caution. THC is secreted in breast milk, and infants' developing brains remain vulnerable during the first years of life. Breastfeeding individuals should consider the same precautionary approach applied during pregnancy.

The Bigger Conversation

This research sits at the intersection of two important trends: the rapid normalization of cannabis use in American culture and the growing sophistication of prenatal and neurodevelopmental science. As cannabis becomes more accessible and socially accepted, the need for rigorous, nuanced public health communication becomes more urgent.

The goal isn't to stigmatize cannabis users or to roll back legalization progress. It's to ensure that the same evidence-based approach that guides recommendations about alcohol, tobacco, and pharmaceutical medications during pregnancy is applied to cannabis as well. Pregnant individuals deserve clear, honest information that respects their autonomy while accurately communicating what the science currently shows.

As researchers continue to investigate the mechanisms linking prenatal THC exposure to developmental outcomes, the most responsible message remains unchanged: when it comes to pregnancy, the safest amount of THC is none.